Document Type: Brief Communication

Authors

1 MD, PhD, Department of Radiation Oncology, Edward Hines Jr VA Hospital, Hines, IL 60141, United States

2 PhD, Bevelacqua Resources, Richland, Washington 99352, United States

3 PhD, National Centre for Nuclear Research, Otwock-Świerk, Poland

4 MD, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

5 PhD, Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

6 PhD, Department of Medical Physics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

7 PhD, Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, United States

Abstract

Abscopal effect, a radiobiology term meaning “away from target”, was practically unheard of just ten years ago. This effect describes the elimination and cure of a non-treated tumor when another part of the body is irradiated. Successful treatment of cancer in patients with multiple metastatic foci has sporadically been reported. Abscopal effect after radiotherapy has been introduced as the key factor which induced an anticancer response in these metastatic lesions. Moreover, not receiving chemotherapy is reported to have a role in cancer regression after radiotherapy. Given this consideration, it can be hypothesized that standard radiotherapy doses, which usually classified as high-dose, may cause cancer cells to expose or release their sequestered antigens that had been previously masked. Furthermore, radiotherapy can decrease the suppressive effect of regulatory T cells which usually down modulate immune responses against cancers. Moreover, some data show that low dose total-body irradiation (TBI) alone (without standard localized high dose radiotherapy) may cause suppression of distant metastasis of tumor cells. Induction of a “whole body abscopal effect” can be involved in suppression of distant metastasis. Here we discuss whether cancer treatments could be more successful if immune system is boosted, not destroyed by the treatments such as chemotherapy.

Keywords

  1. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1:365-72. doi: 10.1158/2326-6066.CIR-13-0115. PubMed PMID: 24563870. PubMed PMCID: PMC3930458.
  2. Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18:313-22. doi: 10.1038/nrc.2018.6. PubMed PMID: 29449659. PubMed PMCID: PMC5912991.
  3. Pleyers C, Piret P, Rorive A, Coucke PA. Could we consider that radiotherapy is effective outside the irradiation area? The abscopal effec]. Rev Med Liege. 2018;73:17-21. PubMed PMID: 29388406.
  4. Pouget JP, Georgakilas AG, Ravanat JL. Targeted and Off-Target (Bystander and Abscopal) Effects of Radiation Therapy: Redox Mechanisms and Risk/Benefit Analysis. Antioxid Redox Signal. 2018;29:1447-87. doi: 10.1089/ars.2017.7267. PubMed PMID: 29350049. PubMed PMCID: PMC6199630.
  5. Azami A, Suzuki N, Azami Y, Seto I, Sato A, Takano Y, et al. Abscopal effect following radiation monotherapy in breast cancer: A case report. Mol Clin Oncol. 2018;9:283-6. doi: 10.3892/mco.2018.1677. PubMed PMID: 30155251. PubMed PMCID: PMC6109680.
  6. Welsh J. Disappearing act: an athletic young man’s skin cancer is spreading rapidly and is likely to be fatal—then his health takes a strange turn. Discover Magazine. 2014:24-6.
  7. Li F, Zhao Y, Wei L, Li S, Liu J. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol Ther. 2018;19:695-705. doi: 10.1080/15384047.2018.1450116. PubMed PMID: 29621426. PubMed PMCID: PMC6067871.
  8. Zhang X, Niedermann G. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response. Int J Radiat Oncol Biol Phys. 2018;101:63-73. doi: 10.1016/j.ijrobp.2018.01.094. PubMed PMID: 29534901.
  9. Liu R, Xiong S, Zhang L, Chu Y. Enhancement of antitumor immunity by low-dose total body irradiationis associated with selectively decreasing the proportion and number of T regulatory cells. Cell Mol Immunol. 2010;7:157-62. doi: 10.1038/cmi.2009.117. PubMed PMID: 20140010. PubMed PMCID: PMC4001896.
  10. Palmer S, Albergante L, Blackburn CC, Newman TJ. Thymic involution and rising disease incidence with age. Proc Natl Acad Sci U S A. 2018;115:1883-8. doi: 10.1073/pnas.1714478115. PubMed PMID: 29432166. PubMed PMCID: PMC5828591.
  11. Mortazavi SMJ. Shortcomings of the immunological model of carcinogenesis. Proc Natl Acad Sci U S A. 2018;115:E4318. doi: 10.1073/pnas.1802507115. PubMed PMID: 29669916. PubMed PMCID: PMC5949006.
  12. Blyth BJ, Cole AJ, MacManus MP, Martin OA. Radiation therapy-induced metastasis: radiobiology and clinical implications. Clin Exp Metastasis. 2018;35:223-36. doi: 10.1007/s10585-017-9867-5. PubMed PMID: 29159430.
  13. Coskun T, Kosova F, Ari Z, Sakarya A, Kaya Y. Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer. Mol Clin Oncol. 2016;4:893-7. doi: 10.3892/mco.2016.815. PubMed PMID: 27123303. PubMed PMCID: PMC4840827.
  14. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7. doi: 10.1038/nature01322. PubMed PMID: 12490959. PubMed PMCID: PMC2803035.
  15. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41:503-10. doi: 10.1016/j.ctrv.2015.03.011. PubMed PMID: 25872878. PubMed PMCID: PMC4816218.
  16. Johnson CB, Jagsi R. The Promise of the Abscopal Effect and the Future of Trials Combining Immunotherapy and Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016;95:1254-6. doi: 10.1016/j.ijrobp.2016.02.067. PubMed PMID: 27354132.
  17. Du B, Jiang Q-L, Cleveland J, Liu B-R, Zhang D. Targeting Toll-like receptors against cancer. Journal of Cancer Metastasis and Treatment. 2016;2:464.
  18. Lim YT. Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease. Clin Exp Vaccine Res. 2015;4:54-8. doi: 10.7774/cevr.2015.4.1.54. PubMed PMID: 25648865. PubMed PMCID: PMC4313109.
  19. Loyola University Health System [Internet]. Combining radiation with immunotherapy showing promise against melanoma. [Cited 19 May 2016]. Available from: www.sciencedaily.com/releases/2016/05/160519151859.htm
  20. Stang K, Silva S, Block AM, Welsh JS. The integration of radiation therapy and immunotherapy in melanoma management. Journal of Radiation Oncology. 2016;5:131-42.
  21. Sakamoto K. Radiobiological basis for cancer therapy by total or half-body irradiation. Nonlinearity Biol Toxicol Med. 2004;2:293-316. doi: 10.1080/15401420490900254. PubMed PMID: 19330149. PubMed PMCID: PMC2657505.